Paolo Tarantino: Moderating a Medscape symposium focused on HR+/HER2 at SABCS24
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on LinkedIn:
“HR+/HER2- is the most common breast cancer subtype and the one with the highest number of recent drug approvals in the metastatic setting.
At SABCS24, I’ll have the honor of moderating a Medscape symposium focused on this subtype with Drs. Dejan Juric and Mariana Chavez MacGregor, where we will put the recent approvals into context and discuss common challenges and opportunities in the field.”
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
More posts featuring Paolo Tarantino.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023